Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2025 Earnings Call Transcript November 3, 2025Axsome Therapeutics, Inc. misses on earnings expectations.
Axsome Therapeutics Inc. (AXSM)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 900,000 | $109,305,000 | +13% | 3.05% |
| 2. | OrbiMed Advisors Samuel Isaly | 531,800 | $64,587,110 | +25% | 1.52% |
| 3. | Partner Fund Management Christopher Medlock James | 530,332 | $64,408,821 | +10% | 4.95% |
| 4. | Biotechnology Value Fund / BVF Inc Mark Lampert | 486,757 | $59,116,638 | -72% | 2.4% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 445,000 | $54,045,250 | -1% | 0.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $127.40 | 488 | $62,171.20 | 48,212 | 2025-09-08 | Filing | |
| $127.30 | 287 | $36,535.10 | 47,724 | 2025-09-08 | Filing | |
| $127.20 | 800 | $101,760.00 | 47,437 | 2025-09-08 | Filing | |
| $37.30 | 3,950 | $147,350.01 | 120,756 | 2021-11-19 | Filing | |
| $35.20 | 142 | $4,998.40 | 142 | 2021-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.49 | 21,775 | $2,928,519.75 | 7,229 | 2025-11-05 | Filing | |
| $133.79 | 50,459 | $6,750,909.61 | 7,229 | 2025-11-04 | Filing | |
| $132.34 | 91,705 | $12,136,239.70 | 7,229 | 2025-11-03 | Filing | |
| $118.84 | 12,774 | $1,518,062.16 | 7,229 | 2025-10-08 | Filing | |
| $118.77 | 13,390 | $1,590,330.30 | 7,229 | 2025-10-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,180,646 | $507,739,457 | 0.01% | |
| 2. | 3,790,929 | $460,408,328 | 0.01% | |
| 3. | 1,334,560 | $162,082,313 | 0.03% | |
| 4. | 1,118,883 | $135,888,340 | 1.67% | |
| 5. | 1,084,536 | $131,717,000 | 0.15% |
News See All
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best biotech stocks to buy. Following a recent discussion with the senior management at Axsome Therapeutics Inc.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
H.C. Wainwright Reaffirms Buy on Axsome (AXSM) Following Generic Challenge to Portfolio
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best mid-cap stocks with huge upside potential. H.C. Wainwright reaffirmed its Buy rating and $180 price target for Axsome Therapeutics Inc.
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Axsome Therapeutics Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note this call is being recorded.
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Biotech Stocks with Huge Upside Potential.